07:00 , Aug 4, 2003 |  BioCentury  |  Strategy

Commercial status

Commercial status Company Country Acambis (LSE:ACM; ACAM) U.K. Actelion (SWX:ATLN) Switzerland Advanced Medical (LSE:AMS) U.K. Alltracel (LSE:ALT) Ireland Bavarian Nordic (CSE:BAVA) Denmark Berna Biotech (SWX:BERN) Switzerland BioPhausia (SSE:BIOP) Sweden Biora (SSE:BIOR) Sweden BioTissue (FSE:BTS) Germany...
07:00 , Aug 4, 2003 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Notes Current cash Cash reporting date Operating loss Op loss period 7/14 BioTissue (FSE:BTS) NA Filed for insolvency after failing to close a funding round. Will start discussions with...
07:00 , Jul 7, 2003 |  BC Week In Review  |  Company News

Biotissue biomaterial/skin/wound news

BTS said it had filed for insolvency, because it was unable to close a funding round. BTS will continue business for the present and also will start discussions with an insolvency manager. BioTissue Technologies AG...
08:00 , Jan 6, 2003 |  BC Week In Review  |  Company News

Biotissue deal

BTS said it signed a cooperation contract with an undisclosed supplier of prosthetic implants covering a joint project to develop a three-dimensional bone consisting of calcium phosphate and patient bone cells. BioTissue Technologies AG (NMarkt:BTS),...
07:00 , Sep 3, 2002 |  BC Week In Review  |  Clinical News

BioSeed-S: Post-marketing study; marketed

Interim data from a European post-marketing study in 62 patients with chronic venous leg ulcers showed BioSeed-S was better than standard therapy in terms of frequency of wound healing and healing time. The study is...
07:00 , Aug 26, 2002 |  BC Week In Review  |  Company News

Biotissue, Cell-Lining GmbH deal

BTS exercised its option to acquire a 51% stake in Cell-Lining, a tissue engineering company. In July 2001, the companies agreed to develop an artificial blood vessel coated with autologous cells developed by Cell-Lining (see...
07:00 , Aug 26, 2002 |  BioCentury  |  Finance

Ebb & Flow

The upswing in U.S. biotech stocks is leading to hopes in Europe that the long down trend has been stopped, at least through year end if not for the long term. Last week, the BioCentury...
07:00 , Aug 21, 2002 |  BC Extra  |  Company News

BioTissue acquires stake in Cell-Lining

BioTissue (NMarkt:BTS) exercised its option to acquire a 51% holding in Cell-Lining (Berlin, Germany). In July, the companies partnered to develop an artificial blood vessel coated with autologous cells developed by Cell-Lining. BTS will take...
07:00 , Jul 1, 2002 |  BioCentury  |  Finance

European IPO class of 2000

European IPO class of 2000 Company Amt raised at IPO (M) Mkt cap at IPO (M) Mkt cap at June 28 (M) % chg from IPO Cash at March 31(M) Actelion $140.5 $739.2 $757.3 2%...
07:00 , May 13, 2002 |  BioCentury  |  Finance

Ebb & Flow

A little more than two years after its hyped-up creation, a piece of the Franco-American venture ValiGen N.V. filed for bankruptcy protection last week, and the financial outlook for its other ventures remain uncertain. ValiGen...